Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy